Scientific publications

TPS in prostate cancer

Rodríguez-Rubio FI, Monreal I [SP], Robles JE [SP], Martín-Marquina A, Abad JI, Rosell D [SP], Berián JM.
Departamento de Urología, Facultad de Medicina, Universidad de Navarra, Pamplona.

Magazine: Actas Urológicas Españolas

Date: Feb 1, 1995

Biochemistry [SP] Urology [SP]

A study of the tumour proliferation marker TPS in prostate cancer has been carried out.

The levels of this marker were determined in the following groups: controls (n = 51), prostate hyperplasia (n = 17), prostate cancer in clinical remission (n = 15), and progressive prostate cancer (n = 13). An upper normal limit of 129 U/l (percentile 95) was established.

When the progressive disease group was compared with the other groups, a significant difference (p < 0.001) was found. Sensitivity, specificity and positive predictive value obtained in order to dismiss progression were 71%, 94% and 62% respectively.

CITATION  Actas Urol Esp. 1995 Feb;19(2):131-3

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra